Project Grant R01CA296203
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $169,776 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The project, titled "Unraveling Myeloid-Mediated Mechanisms of Immunotherapy Resistance in Prostate Cancer Bone Metastases at Single-Cell Resolution," aims to investigate the role of specific myeloid cell subsets in mediating resistance to immune checkpoint inhibitors in metastatic castration-resistant...
- The University of Pennsylvania received a $371,719 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) to conduct research towards characterizing epigenetic targets in prostate cancer. The 5-year project, awarded on March 1, 2025, aims to identify, characterize, and therapeutically target co-factors and chromatin-associated proteins involved in the androgen receptor signaling pathway in prostate cancer. Specifically, the research will...
- This $429,399 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Cedars-Sinai Medical Center in California. The research aims to elucidate the role of extracellular vesicle-enclosed circular RNAs in modulating the immune response to prostate cancer. Specifically, the study will investigate the transfer of extracellular vesicles from prostate cancer cells to macrophages and how the enclosed circular RNAs can trigger...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This federal Project Grant award of $627,474.00 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports a research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative epigenomic methods and signatures to better understand...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center provides $472,458 to conduct research aimed at overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer. The 5-year project, starting December 1, 2024, will investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $570,096 to Northwestern University to conduct research on the role of the EZH2 protein in prostate cancer progression. The project aims to investigate how dysregulation of EZH2 affects RNA modifications, such as N6-methyladenosine (m6A), and how these epigenetic changes contribute to the development of advanced, treatment-resistant prostate cancer. The research seeks to uncover new...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,972 to the University of California, Los Angeles (UCLA) to conduct research on overcoming radiopharmaceutical therapy resistance in prostate cancer. The key focus is to investigate how the enzyme ENPP1 impacts the effectiveness of PSMA-targeting radiopharmaceutical therapy (RPT) by regulating immune signaling pathways in the tumor microenvironment. The research aims to define...
- This federal Project Grant award of $507,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to investigate tumor-intrinsic epigenetic mechanisms that modulate antitumor immune responses in metastatic prostate cancer. The award was made to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution located in New York, NY. This grant aims to advance the...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...